361 related articles for article (PubMed ID: 22320126)
1. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
2. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
4. p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment.
Chen Z; Schubert P; Culibrk B; Devine DV
Transfusion; 2015 Apr; 55(4):848-57. PubMed ID: 25385501
[TBL] [Abstract][Full Text] [Related]
5. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method.
Schubert P; Culibrk B; Karwal S; Serrano K; Levin E; Bu D; Bhakta V; Sheffield WP; Goodrich RP; Devine DV
Transfusion; 2015 Apr; 55(4):815-23. PubMed ID: 25355434
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
7. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
[TBL] [Abstract][Full Text] [Related]
9. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
10. The effect of riboflavin and ultraviolet light on the infectivity of arboviruses.
Faddy HM; Prow NA; Fryk JJ; Hall RA; Keil SD; Goodrich RP; Marks DC
Transfusion; 2015 Apr; 55(4):824-31. PubMed ID: 25370822
[TBL] [Abstract][Full Text] [Related]
11. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD
Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
[TBL] [Abstract][Full Text] [Related]
12. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
[TBL] [Abstract][Full Text] [Related]
13. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
14. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
[TBL] [Abstract][Full Text] [Related]
15. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.
Schubert P; Coupland D; Culibrk B; Goodrich RP; Devine DV
Transfusion; 2013 Dec; 53(12):3164-73. PubMed ID: 23521225
[TBL] [Abstract][Full Text] [Related]
16. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
Picker SM; Tauszig ME; Gathof BS
Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
[TBL] [Abstract][Full Text] [Related]
17. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
18. Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.
Ballester-Servera C; Jimenez-Marco T; Morell-Garcia D; Quetglas-Oliver M; Bautista-Gili AM; Girona-Llobera E
Blood Transfus; 2020 Jul; 18(4):280-289. PubMed ID: 32530405
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
20. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model.
Chi X; Zhi L; Vostal JG
Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
